These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 30230156)

  • 21. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
    Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-risk follicular lymphoma: Treatment options.
    Kahl B
    Hematol Oncol; 2021 Jun; 39 Suppl 1():94-99. PubMed ID: 34105813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
    Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
    Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Management strategy for follicular lymphoma].
    Fukuhara N
    Rinsho Ketsueki; 2017; 58(10):2020-2025. PubMed ID: 28978844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report.
    Cerchione C; Nappi D; Musuraca G; Lucchesi A; Cimmino I; Pane F; De Renzo A; Martinelli G
    Medicine (Baltimore); 2020 Aug; 99(33):e21440. PubMed ID: 32871991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.
    Casulo C; Day B; Dawson KL; Zhou X; Flowers CR; Farber CM; Hainsworth JD; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW
    Ann Oncol; 2015 Nov; 26(11):2311-7. PubMed ID: 26362568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
    Leslie LA
    Curr Treat Options Oncol; 2021 Oct; 22(12):111. PubMed ID: 34694508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.
    Jamois C; Gibiansky E; Gibiansky L; Buchheit V; Sahin D; Cartron G; Marcus R; Hiddemann W; Seymour JF; Strefford JC; Hargreaves CE; Meneses-Lorente G; Frey N; Fingerle-Rowson G
    Br J Clin Pharmacol; 2019 Jul; 85(7):1495-1506. PubMed ID: 30866056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.
    Zohren F; Bruns I; Pechtel S; Schroeder T; Fenk R; Czibere A; Maschmeyer G; Kofahl-Krause D; Niederle N; Heil G; Losem C; Welslau M; Brugger W; Germing U; Kronenwett R; Barth J; Rummel MJ; Haas R; Kobbe G
    Blood; 2015 Sep; 126(12):1407-14. PubMed ID: 26239087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Follicular lymphoma: 2012 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Standard treatment and future perspectives for follicular lymphoma].
    Kameoka Y
    Rinsho Ketsueki; 2022; 63(9):1135-1144. PubMed ID: 36198539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
    Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
    Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.
    Igarashi T; Ogura M; Itoh K; Taniwaki M; Ando K; Kuroda Y; Yamamoto K; Uike N; Tomita A; Nagai H; Kurosawa M; Mori S; Nawano S; Terauchi T; Ohashi Y; Tobinai K
    Int J Hematol; 2016 Dec; 104(6):700-708. PubMed ID: 27714587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
    Chiu H; Trisal P; Bjorklund C; Carrancio S; Toraño EG; Guarinos C; Papazoglou D; Hagner PR; Beldi-Ferchiou A; Tarte K; Delfau-Larue MH; Morschhauser F; Ramsay AG; Gandhi AK
    Br J Haematol; 2019 Apr; 185(2):240-253. PubMed ID: 30767211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ki67 proliferation index in follicular lymphoma is associated with favorable outcome in patients treated with R-CHOP.
    Nichols MM; Ondrejka SL; Patil S; Durkin L; Hill BT; Hsi ED
    Leuk Lymphoma; 2023; 64(8):1433-1441. PubMed ID: 37226602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
    Dhillon S
    Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Follicular lymphoma].
    Tomita N
    Nihon Rinsho; 2014 Mar; 72(3):488-92. PubMed ID: 24724409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obinutuzumab in follicular lymphoma.
    Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
    Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of rituximab in patients with follicular lymphoma.
    Marcus R
    Clin Oncol (R Coll Radiol); 2007 Feb; 19(1):38-49. PubMed ID: 17305253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.